Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that co...

Full description

Bibliographic Details
Main Authors: Parvin F. Peddi, Sara A. Hurvitz
Format: Article
Language:English
Published: SAGE Publishing 2014-09-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758834014539183

Similar Items

Similar Items